Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.01
Dollar change
+0.02
Percentage change
2.02
%
Index- P/E- EPS (ttm)-0.93 Insider Own11.08% Shs Outstand88.93M Perf Week2.02%
Market Cap90.10M Forward P/E- EPS next Y-0.96 Insider Trans0.10% Shs Float79.33M Perf Month-16.18%
Income-82.09M PEG- EPS next Q-0.22 Inst Own46.03% Short Float1.59% Perf Quarter7.16%
Sales0.32M P/S281.57 EPS this Y8.76% Inst Trans-1.71% Short Ratio2.90 Perf Half Y2.69%
Book/sh2.17 P/B0.47 EPS next Y-12.63% ROA-33.36% Short Interest1.26M Perf Year-16.53%
Cash/sh2.05 P/C0.49 EPS next 5Y- ROE-36.50% 52W Range0.88 - 1.57 Perf YTD4.94%
Dividend Est.- P/FCF- EPS past 5Y8.31% ROI-42.24% 52W High-35.67% Beta1.14
Dividend TTM- Quick Ratio10.25 Sales past 5Y-32.60% Gross Margin98.98% 52W Low14.77% ATR (14)0.07
Dividend Ex-Date- Current Ratio10.25 EPS Y/Y TTM-147.20% Oper. Margin-28723.77% RSI (14)41.72 Volatility5.88% 7.23%
Employees72 Debt/Eq0.01 Sales Y/Y TTM-99.04% Profit Margin-25337.96% Recom1.29 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q14.16% Payout0.00% Rel Volume0.65 Prev Close0.99
Sales Surprise-95.12% EPS Surprise15.15% Sales Q/Q-99.51% EarningsFeb 29 BMO Avg Volume435.69K Price1.01
SMA20-10.54% SMA50-4.14% SMA200-4.29% Trades Volume286,704 Change2.02%
Date Action Analyst Rating Change Price Target Change
May-23-23Initiated Robert W. Baird Outperform $7
Sep-07-22Initiated CapitalOne Overweight $7
Apr-29-21Initiated Maxim Group Buy $20
Apr-23-21Resumed Cowen Outperform $10 → $18
Mar-31-21Initiated Wedbush Outperform $21
Mar-31-21Initiated Jefferies Buy $21
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Mar-21-24 07:00AM
Mar-01-24 09:06AM
Feb-29-24 11:25PM
08:11AM
07:27AM
07:00AM Loading…
07:00AM
Feb-27-24 07:00AM
Feb-22-24 07:00AM
Dec-29-23 07:00AM
Dec-04-23 07:00AM
Nov-24-23 07:00AM
Nov-16-23 07:00AM
Nov-03-23 09:12AM
01:34AM
Nov-02-23 10:08AM
07:10AM Loading…
07:10AM
07:00AM
Oct-26-23 07:00AM
Oct-23-23 10:08AM
Sep-05-23 07:00AM
Aug-16-23 10:05AM
Aug-11-23 06:15AM
Aug-03-23 08:25AM
07:19AM
07:00AM
Jul-31-23 07:54AM
Jul-30-23 02:17PM
Jul-28-23 04:19PM
Jul-27-23 10:53AM
07:00AM
06:00AM Loading…
06:00AM
Jul-11-23 08:53PM
Jun-28-23 02:58PM
Jun-27-23 04:05PM
Jun-01-23 08:04PM
May-31-23 04:01PM
May-25-23 07:00AM
May-05-23 06:11AM
May-04-23 08:25AM
07:17AM
07:00AM
Apr-27-23 07:00AM
Apr-18-23 04:01PM
Mar-29-23 10:13AM
09:35AM
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
07:00AM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
Dec-12-22 01:41PM
Dec-08-22 05:00PM
Nov-29-22 12:00PM
Nov-10-22 04:30PM
09:00AM
Nov-07-22 06:06AM
Nov-04-22 12:27PM
07:46AM
Nov-03-22 08:15AM
07:00AM
Nov-01-22 10:01AM
Oct-27-22 04:30PM
10:02AM
Oct-26-22 11:52AM
Sep-27-22 09:59PM
02:52PM
10:13AM
Sep-26-22 04:05PM
Sep-10-22 09:16AM
Sep-06-22 07:00AM
Sep-01-22 08:48AM
Aug-30-22 02:17PM
Aug-29-22 10:45AM
Aug-17-22 09:29AM
Aug-09-22 04:00AM
Aug-08-22 04:01PM
07:00AM
Aug-02-22 07:00AM
Aug-01-22 04:01PM
Jul-25-22 04:30PM
09:42AM
Jul-16-22 09:45AM
Jun-24-22 03:08PM
10:37AM
10:06AM
Jun-23-22 09:15AM
Jun-22-22 07:00AM
Jun-16-22 09:10AM
Jun-09-22 06:28AM
Jun-01-22 04:30PM
May-24-22 08:04AM
05:55AM
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jakeman DavidVP OF FINANCE AND ACCOUNTINGFeb 14 '24Sale1.042,6602,777141,232Feb 16 08:00 PM
LaSpaluto MichelleCHIEF FINANCIAL OFFICERFeb 14 '24Sale1.041,9402,023110,999Feb 16 08:01 PM
Andriole Michael T.PRESIDENT AND CEOFeb 14 '24Sale1.041,7441,809447,021Feb 16 08:02 PM
MIDDLETON FRED ADirectorNov 17 '23Buy0.9617,29516,522100,000Nov 20 03:28 PM
MIDDLETON FRED ADirectorNov 10 '23Buy0.922,7052,48982,705Nov 13 04:39 PM
Jakeman DavidVP of Finance and AccountingSep 28 '23Sale0.993,6103,584133,142Sep 28 04:17 PM
MIDDLETON FRED ADirectorSep 25 '23Buy0.9820,00019,63680,000Sep 26 03:58 PM
Andriole Michael T.Chief Business Officer and CFOMay 18 '23Buy1.1451,70059,150357,015May 19 11:41 AM
Sherman Michael A.Chief Executive OfficerMay 12 '23Buy1.1287,00097,65287,000May 16 04:05 PM
DEMSKI MARTHA JDirectorMay 10 '23Buy1.1118,00019,98072,055May 11 12:26 PM
Meyer Robert J.DirectorMay 08 '23Buy1.148,7509,97535,150May 10 12:51 PM